CliffBio
biologic

Abecma

idecabtagene vicleucel

Loss of exclusivity—loss of exclusivity
CompanyCelgene Corporation, a Bristol-Myers Squibb Company

Drug detail

Brand nameAbecma
Active ingredientidecabtagene vicleucel
Strength300 to 460 X 10^6 CHIMERIC ANTIGEN RECEPTOR (CAR)-POSITIVE T CELLS
Dosage formSuspension
RouteIntravenous
ModalityBiologic
Marketing statusRx

More from Celgene Corporation, a Bristol-Myers Squibb Company

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Abecma patent cliff — loss of exclusivity — | CliffBio